Login to Your Account

FDA puts partial hold on Zafgen trials; screening for PWS patients

By Michael Fitzhugh
Staff Writer

Friday, October 16, 2015
A partial clinical hold placed by the FDA on two Zafgen Inc. trials following a participant’s death continued to hold company shares (NASDAQ:ZFGN) near an all-time low Friday, pushing them $10.66 lower, or 50.7 percent, to close at $10.36.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription